Calendula
PreclinicalSmall molecule
Calendula is one of 51 small molecule programs targeting Dermatitis. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tykerb
GSKPreclinical
Avastin
BBio-Thera Solutions
Preclinical
Megace
Bristol-Myers SquibbPreclinical
Lexiscan
AstellasPreclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Bisphosphonate
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calendula. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- OOHSU Knight Cancer Institute